Frontiers | Targeting KRAS Mutant in Non-Small Cell Lung Cancer: Novel Insights Into Therapeutic Strategies
Frontiers | Resistance to KRASG12C Inhibitors in Non-Small Cell Lung Cancer
KRAS: feeding pancreatic cancer proliferation: Trends in Biochemical Sciences
KRAS mutation identified in a patient with melorheostosis and extended lymphangiomatosis treated with sirolimus and trametinib - Lacasta‐Plasin - 2021 - Clinical Genetics - Wiley Online Library
Cureus | KRAS/NRAS/BRAF Mutation Rate in Saudi Academic Hospital Patients With Colorectal Cancer | Article
Adagrasib with or without Cetuximab in Colorectal Cancer with Mutated KRAS G12C | NEJM
Synthetic Lethal Interaction between Oncogenic KRAS Dependency and STK33 Suppression in Human Cancer Cells: Cell
KRAS mutation: from undruggable to druggable in cancer | Signal Transduction and Targeted Therapy
Sotorasib for Lung Cancers with KRAS p.G12C Mutation | NEJM
Partnership seeks to develop KRAS degraders for cancer therapy | Frederick National Laboratory
Somatic Gain of KRAS Function in the Endothelium Is Sufficient to Cause Vascular Malformations That Require MEK but Not PI3K Signaling | Circulation Research
KRAS-mutant non-small cell lung cancer: Converging small molecules and immune checkpoint inhibition - eBioMedicine
Chemically modified MIR143-3p exhibited anti-cancer effects by impairing the KRAS network in colorectal cancer cells: Molecular Therapy - Nucleic Acids
Small molecule combats cancer-causing KRAS protein at last
KRAS Biomarker | Colorectal Cancer Alliance
Targeting KRAS in Lung Cancer: The Past, Present, and Future - ILCN.org (ILCN/WCLC)
KRAS - Wikipedia
Partnership seeks to develop KRAS degraders for cancer therapy | Frederick National Laboratory
KRAS inhibitors, approved | Nature Cancer
Precision oncology provides opportunities for targeting KRAS-inhibitor resistance: Trends in Cancer
The current state of the art and future trends in RAS-targeted cancer therapies | Nature Reviews Clinical Oncology
The improbable targeted therapy: KRAS as an emerging target in non-small cell lung cancer (NSCLC) - ScienceDirect
Targeting mutated GTPase KRAS in tumor therapies - ScienceDirect
Cancers | Free Full-Text | KRAS in NSCLC: State of the Art and Future Perspectives
Targeted Therapies Are Game Changers for Lung Cancer Patients with a KRAS Mutation | Fox Chase Cancer Center - Philadelphia PA
